WO2018226058A3 - 콜라겐 타입 ι 및 색소 상피성 인자 펩타이드를 유효성분으로 함유하는 신생혈관질환 예방 또는 치료용 약학조성물 - Google Patents

콜라겐 타입 ι 및 색소 상피성 인자 펩타이드를 유효성분으로 함유하는 신생혈관질환 예방 또는 치료용 약학조성물 Download PDF

Info

Publication number
WO2018226058A3
WO2018226058A3 PCT/KR2018/006506 KR2018006506W WO2018226058A3 WO 2018226058 A3 WO2018226058 A3 WO 2018226058A3 KR 2018006506 W KR2018006506 W KR 2018006506W WO 2018226058 A3 WO2018226058 A3 WO 2018226058A3
Authority
WO
WIPO (PCT)
Prior art keywords
pedf
preventing
pharmaceutical composition
active ingredients
pigment epithelium
Prior art date
Application number
PCT/KR2018/006506
Other languages
English (en)
French (fr)
Other versions
WO2018226058A2 (ko
WO2018226058A9 (ko
Inventor
박세광
노국환
김현웅
박성재
Original Assignee
인제대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인제대학교 산학협력단 filed Critical 인제대학교 산학협력단
Priority to CN201880037986.6A priority Critical patent/CN110869045B/zh
Priority to EP18814409.1A priority patent/EP3636275B1/en
Priority to US16/619,947 priority patent/US11197918B2/en
Publication of WO2018226058A2 publication Critical patent/WO2018226058A2/ko
Publication of WO2018226058A3 publication Critical patent/WO2018226058A3/ko
Publication of WO2018226058A9 publication Critical patent/WO2018226058A9/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

본 발명은 콜라겐 및 34-mer 색소 상피성 인자(PEDF) 펩타이드를 유효성분으로 함유하는 신생혈관질환 예방 또는 치료용 약학조성물에 관한 것으로, 보다 상세하게는 콜라겐 타입 Ⅰ과 34-mer PEDF 펩타이드 병용 투여를 통하여 PEDF의 짧은 항혈관신생 활성주기에 증가시키고, PEDF의 투여 용량 범위를 확장시킬 수 있으므로, 종래의 PEDF 잦은 주입에 따른 불편함과 그에 따른 부작용 문제를 해결할 수 있으며, 다양한 혈관신생질환 치료제로 적용이 가능하다.
PCT/KR2018/006506 2017-06-08 2018-06-08 콜라겐 타입 ι 및 색소 상피성 인자 펩타이드를 유효성분으로 함유하는 신생혈관질환 예방 또는 치료용 약학조성물 WO2018226058A2 (ko)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201880037986.6A CN110869045B (zh) 2017-06-08 2018-06-08 包含i型胶原及色素上皮衍生因子肽作为有效成分的预防或治疗新生血管性疾病的药物组合物
EP18814409.1A EP3636275B1 (en) 2017-06-08 2018-06-08 Pharmaceutical composition for preventing or treating neovascular disease, containing collagen type i and pigment epithelium derived factor peptide as active ingredients
US16/619,947 US11197918B2 (en) 2017-06-08 2018-06-08 Pharmaceutical composition for preventing or treating neovascular disease, containing collagen type i and pigment epithelium derived factor peptide as active ingredients

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2017-0071521 2017-06-08
KR1020170071521A KR101906494B1 (ko) 2017-06-08 2017-06-08 콜라겐 타입 ι 및 색소 상피성 인자 펩타이드를 유효성분으로 함유하는 신생혈관질환 예방 또는 치료용 약학조성물

Publications (3)

Publication Number Publication Date
WO2018226058A2 WO2018226058A2 (ko) 2018-12-13
WO2018226058A3 true WO2018226058A3 (ko) 2019-04-11
WO2018226058A9 WO2018226058A9 (ko) 2019-05-31

Family

ID=64566002

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/006506 WO2018226058A2 (ko) 2017-06-08 2018-06-08 콜라겐 타입 ι 및 색소 상피성 인자 펩타이드를 유효성분으로 함유하는 신생혈관질환 예방 또는 치료용 약학조성물

Country Status (5)

Country Link
US (1) US11197918B2 (ko)
EP (1) EP3636275B1 (ko)
KR (1) KR101906494B1 (ko)
CN (1) CN110869045B (ko)
WO (1) WO2018226058A2 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020213993A1 (ko) * 2019-04-18 2020-10-22 한양대학교 에리카산학협력단 신혈관 생성 억제용 융합 폴리펩타이드, 다가성 신혈관 생성 억제용 펩타이드를 가진 융합단백질 나노케이지 및 이의 테라노스틱스 용도
KR102412681B1 (ko) * 2019-04-18 2022-06-27 한양대학교 에리카산학협력단 다중 자극 반응성 블록 코폴리펩타이드 기반 약물전달체
KR102413729B1 (ko) * 2019-04-18 2022-06-29 한양대학교 에리카산학협력단 신혈관 생성 억제용 융합 폴리펩타이드, 다가성 신혈관 생성 억제용 펩타이드를 가진 융합단백질 나노케이지 및 이의 테라노스틱스 용도
WO2024144099A1 (ko) * 2022-12-27 2024-07-04 주식회사 넥스세라 안구 질환 치료를 위한 효율적인 약물 전달 플랫폼

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016014786A2 (en) * 2014-07-24 2016-01-28 Yale University Pigment epithelium-derived factor (pedf) and peptide derivatives thereof for use in osteoblast differentiation and bone growth

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004027027A2 (en) * 2002-09-18 2004-04-01 Trustees Of The University Of Pennsylvania Method of inhibiting choroidal neovascularization
JP2005336159A (ja) * 2004-04-28 2005-12-08 Univ Kurume Ｎａｄｐｈオキシダーゼ活性を抑制する色素上皮由来因子の新規治療用途
WO2006046584A1 (ja) 2004-10-26 2006-05-04 Santen Pharmaceutical Co., Ltd. 視細胞障害治療剤
KR20170123502A (ko) 2016-04-29 2017-11-08 부경대학교 산학협력단 콜라겐 및 색소 상피성 인자를 유효성분으로 함유하는 신생혈관질환 예방 또는 치료용 약학조성물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016014786A2 (en) * 2014-07-24 2016-01-28 Yale University Pigment epithelium-derived factor (pedf) and peptide derivatives thereof for use in osteoblast differentiation and bone growth

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BELKACEMI, LOUIZA: "Anti-tumor effects of pigment epithelium-derived factor (PEDF): implication for cancer therapy. A mini-review", JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, vol. 35, 2016, pages 1 - 14, XP055590136 *
FILLEUR, STEPHANIE: "Two functional epitopes of pigment epithelial-derived factor block angiogenesis and induce differentiation in prostate cancer", CANCER RESEARCH, vol. 65, no. 12, 2005, pages 5144 - 5152, XP002651215, DOI: doi:10.1158/0008-5472.can-04-3744 *
HE, XUEMIN: "PEDF and its roles in physiological and pathological conditions: implication in diabetic and hypoxia-induced angiogenic diseases", CLINICAL SCIENCE, vol. 128, no. 11, 2015, pages 805 - 823, XP055590150 *
HOSOMICHI, JUN: "Involvement of the collagen I-binding motif in the anti-angiogenic activity of pigment epithelium-derived factor", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 335, no. 3, 2005, pages 756 - 761, XP005035570 *

Also Published As

Publication number Publication date
WO2018226058A2 (ko) 2018-12-13
CN110869045A (zh) 2020-03-06
CN110869045B (zh) 2023-10-20
US11197918B2 (en) 2021-12-14
EP3636275B1 (en) 2023-08-09
US20210077599A1 (en) 2021-03-18
EP3636275A4 (en) 2021-03-10
EP3636275A2 (en) 2020-04-15
KR101906494B1 (ko) 2018-12-05
WO2018226058A9 (ko) 2019-05-31

Similar Documents

Publication Publication Date Title
WO2018226058A3 (ko) 콜라겐 타입 ι 및 색소 상피성 인자 펩타이드를 유효성분으로 함유하는 신생혈관질환 예방 또는 치료용 약학조성물
PH12017502092A1 (en) Topical pharmaceutical compositions
JOP20200156A1 (ar) إيسكيتامين لعلاج الاكتئاب
WO2017155232A3 (ko) 발모 촉진 활성 및/또는 멜라닌 생성 촉진 활성을 나타내는 펩타이드 및 이의 용도
MX2019013799A (es) Peptido novedoso y composicion farmaceutica para tratar una enfermedad ocular que comprende el mismo como un ingrediente farmaceutico activo.
MY201105A (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
MX2020010907A (es) Mejora de suministro de agentes activos lipofilicos a traves de la barrera hematoencefalica y metodos para tratar trastornos del sistema nervioso central.
PH12014501620A1 (en) Compositions and methods for the treatment of hepatic diseases and disorders
UA117506C2 (uk) Фармацевтичний препарат, який містить сполуку піридиламінооцтової кислоти
MX2011011459A (es) Formulacion de clavulanato para neuroproteccion y tratamiento de trastornos neurodegenerativos.
MX2018000084A (es) Una composicion farmaceutica que comprende amlodipino, valsartan y rosuvastatina.
JOP20210185A1 (ar) مركبات هالو-آلِّيلامين واستخدامها
MX2021009219A (es) Triamtereno o nolatrexed para su uso en el tratamiento de la fenilcetonuria.
NO20075945L (no) Behandling, prevensjon og ameliorasjon av lungelidelser assosiert med kjemoterapi eller radioterapi med aktive vitamin D sammensetninger eller imitatorer derav
BR112015027992A2 (pt) uso de ácido petroselínico para combater desordens estéticas da figura do corpo
MX2020013692A (es) Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma.
WO2016191458A3 (en) Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
MX2021006654A (es) Uso de extracto de cocculus hirsutus para tratar dengue.
MX2020007222A (es) Metodos para el tratamiento de afecciones inflamatorias de la piel.
MX2023003401A (es) Composicion farmaceutica para prevenir o tratar enfermedad hepatica colestasica, que contiene beta-lapachona como ingrediente activo.
NZ708511A (en) Methods for controlling blood pressure and reducing dyspnea in heart failure
MX2021008687A (es) Una composicion para el tratamiento de la periodontitis y la regeneracion de la papila interdental.
WO2019017676A3 (ko) 에틸바닐린을 유효성분으로 함유하는 근력강화, 근육증강, 근육분화, 근육재생 또는 근감소증 억제효과를 갖는 조성물
WO2019066548A3 (ko) 심부전의 예방 또는 치료용 약학적 조성물
MX2018013474A (es) Acidos carboxilicos para aplicacion en la primera infancia.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18814409

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018814409

Country of ref document: EP

Effective date: 20200108